Blinatumomab and olverembatinib for Ph-positive ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two drugs—blinatumomab (an immune therapy) and olverembatinib (a targeted pill)—for people with a specific type of ALL that has the Ph chromosome or BCR::ABL1 gene. It aims to see if this combination works well in controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have Ph-positive or BCR::ABL1-positive ALL that is either newly diagnosed or has come back/not responded to treatment.
- If newly diagnosed, you can have had only 1 or 2 rounds of chemo (with or without other TKIs).
- You must be in fairly good physical condition (ECOG score of 2 or less).
- Your liver, pancreas, and heart must be functioning reasonably well.
- You must be willing to use effective contraception, and have a negative pregnancy test if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests two medicines together: olverembatinib (a pill) and blinatumomab (given by infusion). It is for people who are newly diagnosed with Ph+ ALL and have not had chemotherapy yet. The goal is to see if this combination works well and is safe.
This trial tests a combination of two drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
Hear when a new Blinatumomab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.